Novo Nordisk Pharmatech and Novozymes enter into enzyme partnership

Going forward, Novo Nordisk Pharmatech and Novozymes will collaborate on developing enzymes to be used in biotechnological drug development.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk Pharmatech and Novozymes have partnered up to developed specialty enzymes meant for biopharma processing and regenerative medicines, the firms announce in a shared press release.

The enzymes will be focused on stem cell and gene therapies in particular.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs